Downloads
Abstract
Background: 25% of women with carcinoma of breast are premenopausal and are at risk for chemotherapy-induced menopause. The objective of this study is to determine the rates of chemotherapy- induced amenorrhea in breast cancer patient with Anthracycline and Taxane containing dose dense adjuvant regimens. There are inadequate data about the impact of these adjuvant regimens on menstrual function in Vietnamese breast cancer patients.
Methods: 48 premenopausal women with carcinoma of breast who were treated with adjuvant anthracycline and taxane-based chemotherapy at National Cancer Hospital of Viet Nam from August 2016 to August 2018. Menstrual status were obtained prospectively.
Results: 48 patients had sufficient follow-up for evaluation. 67% of patients aged 40 years and younger. All patients had regular menses before chemotherapy. 40 patients (83%) developed amenorrhea after finishing adjuvant chemotherapy, and 60% of these patients (40 patients) resumed menstruation at 12 months after chemo. There was a statistically significant correlation between age and the development of amenorrhea, patients older than 40 years had higher risk.
Conclusion: Adjuvant anthracycline and taxane-based chemotherapy induces reversible amenorrhea. Age had impact on development of chemotherapy-induced amenorrhea.
References
ThamYL, Sixton K, Weiss H, Elledge R, Friedman L, Krame R: The rates of chemotherapy-induced amenorrhea in patients treatd with adjuvant doxorubicin and cyclophosphamide fol- lowed by taxane. Am J Clin Oncol 2007, 30:126-132.
Martine Berliere, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008, 8:56 doi:10.1186/1471-2407-8-56.
Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premeno- pausal breast cancer patients: the International Breast Can- cer Study Group. Ann Oncol. 1990;1:183–188.
Zambetti M, Bonadonna G, Valagussa P, et al. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992;11:77–83.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in pre- menopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729.
Monica N. Fornier, M.D, Shanu Modi, M.D., Katherine S. Panageas, Clifford Hudis, M.D., et al: Incidence of Chemotherapy-Induced, Long-Term Amenorrhea in Patients with Breast Carcinoma Age 40 Years and Younger after Adjuvant Anthracycline and Taxane. Cancer 104: 8, October 15, 2005.
Jeanne A. Petrek†, Michelle J. Naughton, L. Douglas Case, Electra D. Paskett, Elizabeth Z. Naftalis, S. Eva Singletary, and Paniti Sukumvanich: Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study. J Clin Oncol 24, 7:4174- 4183, 2006.
Ganz PA, Desmond KA, Belin TR, et al: Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371-2380, 1999.
Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer [Review]. J Clin Oncol 14:1718-1729, 1996.
Minton SE, Munster PN: Chemotherapy induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9:466-472, 2002.
Goldhirsch A, Gelber RD, Castiglione M: The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: The International Breast Cancer Study Group. Ann Oncol 1:183-188, 1990.
Fisher B, Sherman B, Rockette H, et al: L-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: Lack of association of disease free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer 44:847- 857, 1979.
| Published | 27-08-2018 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 50 (2018) | |
| Section | Original article | |
| DOI | ||
| Keywords | mất kinh, ung thư vú amenorrhea, breast cancer |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital